| Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death MS Ricci, SH Kim, K Ogi, JP Plastaras, J Ling, W Wang, Z Jin, YY Liu, ... Cancer cell 12 (1), 66-80, 2007 | 321 | 2007 |
| Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer B Virassamy, F Caramia, P Savas, S Sant, J Wang, SN Christo, A Byrne, ... Cancer Cell 41 (3), 585-601. e8, 2023 | 188 | 2023 |
| Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer SK Down, O Lucas, JR Benson, GC Wishart Oncology Letters 8 (6), 2757-2761, 2014 | 30 | 2014 |
| Management of late relapses after chemotherapy in testicular cancer: optimal outcomes with dose-intense salvage chemotherapy and surgery C Alifrangis, O Lucas, S Benafif, W Ansell, M Greenwood, S Smith, ... European urology focus 7 (4), 835-842, 2021 | 12 | 2021 |
| Characterizing the evolutionary dynamics of cancer proliferation in single-cell clones with SPRINTER O Lucas, S Ward, R Zaidi, A Bunkum, AM Frankell, DA Moore, MS Hill, ... Nature Genetics 57 (1), 103-114, 2025 | 10 | 2025 |
| Replication timing alterations are associated with mutation acquisition during breast and lung cancer evolution M Dietzen, H Zhai, O Lucas, O Pich, C Barrington, WT Lu, S Ward, Y Guo, ... Nature Communications 15 (1), 6039, 2024 | 9 | 2024 |
| Abstract PR010: Linking proliferation rate to the evolution of single-cell primary and metastatic tumor clones O Lucas, S Ward, R Zaidi, A Bunkum, AM Frankell, DA Moore, MS Hill, ... Cancer Research 84 (3_Supplement_2), PR010-PR010, 2024 | 1 | 2024 |
| Investigating the role of altered replication timing during tumor evolution in lung and breast cancer M Dietzen, H Zhai, O Lucas, S Ward, Y Guo, W Ting-Lu, O Pich, ... Cancer Research 82 (12_Supplement), 3620-3620, 2022 | 1 | 2022 |
| Characterising the evolutionary dynamics of cancer proliferation and altered replication timing O Lucas UCL (University College London), 2025 | | 2025 |
| Tracking the evolution of non-small-cell lung cancer: Completion of the TRACERx longitudinal cohort LY Liu, K Haase, AM Leppä, A Azizi, E Hazelwood, T Karasaki, WZ Zhang, ... Cancer Research 85 (8_Supplement_1), 6421-6421, 2025 | | 2025 |
| Triple-negative breast cancer evolution and therapy response: Breast TRACERx I Usaite, TB Watkins, O Lucas, C Marínez-Ruiz, F Legrand, C Lamy, ... Cancer Research 85 (8_Supplement_1), 6613-6613, 2025 | | 2025 |
| 112MO Triple-negative breast cancer evolution and therapy response: Breast TRACERx I Usaite, O Lucas, T Watkins, M Hill, C Martinez-Ruiz, F Legrand, C Lamy, ... ESMO Open 9, 2024 | | 2024 |
| 133P Exploring genomic instability at the single-cell level using a new method for the inference of copy number alterations L Patruno, S Chirrane, O Lucas, R Zaidi, S Ward, M Jamal-Hanjani, ... ESMO Open 9, 2024 | | 2024 |
| 134P SPICE: Probabilistic reconstruction of copy-number evolution in cancer A Bunkum, O Lucas, R Zaidi, N McGranahan, C Swanton, ... ESMO Open 9, 2024 | | 2024 |
| 11P Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations R Zaidi, S Ward, A Bunkum, OJ Lucas, M Hill, D Marinelli, C Lombardelli, ... ESMO Open 8 (1), 2023 | | 2023 |
| Measuring proliferation rates of distinct tumour clones using single-cell DNA sequencing O Lucas, S Ward, R Zaidi, M Hill, E Lim, H Zhai, A Bunkum, S Hessey, ... Cancer Research 83 (7_Supplement), 4277-4277, 2023 | | 2023 |
| Measuring proliferation rates of distinct tumour clones using single-cell DNA sequencing: 7MO OJ Lucas, S Ward, R Zaidi, M Hill, E Lim, H Zhai, M Jamal-Hanjani, ... Annals of Oncology 33, S1385-S1386, 2022 | | 2022 |
| 7MO Measuring proliferation rates of distinct tumour clones using single-cell DNA sequencing OJ Lucas, S Ward, R Zaidi, M Hill, E Lim, H Zhai, M Jamal-Hanjani, ... Annals of Oncology 33, S1385-S1386, 2022 | | 2022 |
| The effect of lowering haematological cut-offs for treatment and blood product support on the deliverability of carboplatin AUC10 in metastatic seminoma S Duncan, O Lucas, MS Chowdhury, P Wilson, C Alifrangis, J Shamash European Urology Supplements 18 (4), 18, 2019 | | 2019 |
| The management of late relapse post chemotherapy in testicular cancer: Optimal outcomes with dose intense salvage chemotherapy and surgery O Lucas, P Wilson, W Ansell, B Thomas, D Berney, J Shamash, ... European Urology Supplements 18 (4), 27, 2019 | | 2019 |
